MesoPher

About Amphera

Amphera is a Dutch biotech advancing MesoPher, an autologous dendritic cell therapy for solid tumors. The platform utilizes PheraLys, an off-the-shelf, allogeneic tumor lysate designed to present a broad spectrum of tumor-associated antigens to the patient's immune system. The company has reported positive Phase II results in resected pancreatic cancer, with data published in the Journal of Clinical Oncology, and is progressing into later-stage clinical development. Amphera operates as a private, pre-revenue entity spun out from Erasmus MC.

About Amphera

Amphera is a Dutch biotech advancing MesoPher, an autologous dendritic cell therapy for solid tumors. The platform utilizes PheraLys, an off-the-shelf, allogeneic tumor lysate designed to present a broad spectrum of tumor-associated antigens to the patient's immune system. The company has reported positive Phase II results in resected pancreatic cancer, with data published in the Journal of Clinical Oncology, and is progressing into later-stage clinical development. Amphera operates as a private, pre-revenue entity spun out from Erasmus MC.

About Amphera

Amphera is a Dutch biotech advancing MesoPher, an autologous dendritic cell therapy for solid tumors. The platform utilizes PheraLys, an off-the-shelf, allogeneic tumor lysate designed to present a broad spectrum of tumor-associated antigens to the patient's immune system. The company has reported positive Phase II results in resected pancreatic cancer, with data published in the Journal of Clinical Oncology, and is progressing into later-stage clinical development. Amphera operates as a private, pre-revenue entity spun out from Erasmus MC.

Therapeutic Areas